1 / 13

Hypermed, Inc.’s Patent-Pending Advanced Rapid Opiate Detox Protocol Stopping addiction in 8 hours without withdrawal an

Hypermed, Inc.’s Patent-Pending Advanced Rapid Opiate Detox Protocol Stopping addiction in 8 hours without withdrawal and without relapse . Market of Rapid Opiate Detox Treatment. 40,000 Americans die every year from opiate drug overdose.

emery
Télécharger la présentation

Hypermed, Inc.’s Patent-Pending Advanced Rapid Opiate Detox Protocol Stopping addiction in 8 hours without withdrawal an

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hypermed, Inc.’s Patent-Pending Advanced Rapid Opiate Detox ProtocolStopping addiction in 8 hours without withdrawal and without relapse

  2. Market of Rapid Opiate Detox Treatment • 40,000 Americans die every year from opiate drug overdose. • Las Vegas Rapid Detox Clinic, owned by Hypermed, uses patent-pending technique to stop opiate addiction in just 8 hours, without withdrawal or relapse. • We have treated 361 patients without complications since 2007, with annual revenue of one million dollars.

  3. Rapid Detox Clinic

  4. We Are Number One on Google • Our website, www.rapiddetoxlasvegas.com is the number one result listing on Google natural search result for keywords “rapid detox”

  5. Patent-Pending Advanced Rapid Opiate Detox (AROD) Protocol Special Features of protocol • 8 hours of treatment, longer and more thorough than any other protocol; patients wake up with no withdrawal. • Utilizing FDA-approved medication Vivitrol, long-acting opiate antagonist, lasting 30 days, to prevent relapse. • Monitoring the brain waves and brain metabolism during the procedure to ensure patient safety

  6. Actual Patient in Advanced Rapid Detox

  7. Published Article on Rapid Detox • Anesthesiology 1999; 91:1639–47 • Title: “Rapid Opioid Detoxification during General Anesthesia, A Review of 20 Patients” • Authors: Carl G. Gold, M.D., M.A.,* David J. Cullen, M.D., M.S.,† • Background: Opioid addiction therapy includes successful detoxification, rehabilitation, and sometimes methadone maintenance. However, the patient may have physical, mental, and emotional pain while trying to achieve abstinence. A new detoxification technique that incorporates general anesthesia uses a high-dose opioid antagonist to compress detoxification to within 6 h while avoiding the withdrawal. • Methods: After Institutional Review Board approval and detailed informed consent, 20 patients, American Society of Anesthesiologists status I–II, addicted to various opioids underwent anesthesia-assisted rapid opioid detoxification. After baseline hemodynamics and withdrawal scores were obtained, anesthesia was induced. After testing with 0.4 mg intravenous naloxone, 4 mg nalmefene, was infused over 2 to 3 h. After emergence, severity of withdrawal was scored before and after administration of 0.4 mg intravenous naloxone. After 24 h, patients began outpatient follow-up treatment while taking oral naltrexone. • Results: All 20 patients were successfully detoxified with no adverse anesthetic events. After the first post-treatment test dose of 0.4 mg naloxone, 13 of 20 patients had no signs of withdrawal and hemodynamic changes were minimal. Withdrawal scores were always very low and similar before and after detoxification. Three of 17 patients (18%) available for follow-up have remained abstinent from opioids since treatment (< 18 months). Four other patients are clean after brief re- lapses.

  8. Addiction BiologyVolume 8 Issue 3 Page 351-358, September 2003 “Rapid detoxification from opioid dependence under general anaesthesia versus standard methadone tapering: abstinence rates and withdrawal distress experiences” • PAUL KRABBE, KONING , NADIA HEINEN , ROBERT LAHEIJ , RM VICTORY VAN 1Department of Medical Technology Assessment University Medical Centre Nijmegen Nijmegen The Netherlands • The aim of this work was to study abstinence rates and withdrawal effects of rapid detoxification of opioid-dependents under general anaesthesia (RD-GA) compared to standard methadone tapering (SMT) using a prospective clinical trial with a follow-up of 3 months. Thirty opioid-dependent patients took part. Outcome measures included urine toxicology screening for opiates to determine abstinence and presence of objective and subjective opioid withdrawal distress symptoms. • Statistically significant differences in abstinence rate between RD-GA and SMT were present after one (RD-GA 100% vs. SMT 40%, p <0.01) and 2 months (RD-GA 93% vs. SMT 33%, p <0.01). After 3 months the difference in abstinence was still substantial, but no longer statistically significant (RD-GA 67% vs. SMT 33%, p =0.14). Objective and subjective withdrawal symptoms showed largely identical outcomes and were equally low in the two groups for those who remained in the study. • There was a considerably higher percentage of abstinence in the RD-GA group after 1, 2 and 3 months of follow-up accompanied by relatively mild withdrawal symptoms of shorter duration. However, if one completes SMT the data suggest a greater chance of staying clean in the long term than those completing RD-GA.

  9. Rapid and Ultrarapid Opioid Detoxification Techniques Patrick G. O'Connor, MD, MPH; Thomas R. Kosten, MD JAMA. 1998;279:229-234. Data Synthesis.— A qualitative analysis was performedon the 12 studies of RD and the 9 studies of URD identifiedin our search. The RD studies enrolled 641 subjects (range forindividual studies, 1-162): 7 were inpatient studies, and theprotocols varied considerably, as did the outcomes assessed.Three RD studies included a control group, 2 used a randomizeddesign, and 3 reported outcomes beyond 12 days. The URD studiesenrolled 424 subjects (range for individual studies, 6-300):all were inpatient studies, the detoxification and anesthesiaprotocols varied, 3 included a control group, 2 used a randomizeddesign, and 2 reported outcomes for URD beyond 7 days.

  10. Anesthesia-Assisted vs Buprenorphine- or Clonidine-Assisted Heroin Detoxification and Naltrexone Induction: A Randomized TrialCollins et al.JAMA 2005;294:903-913. Methods of Detoxification and Their Role in Treating Patients With Opioid DependenceO'ConnorJAMA 2005;294:961-963. The Use of Dexmedetomidine to Facilitate Opioid and Benzodiazepine Detoxification in an InfantFinkel and ElrefaiAnesth. Analg. 2004;98:1658-1659. Complications of Ultrarapid Opioid Detoxification with Subcutaneous Naltrexone PelletsHamilton et al.Acad. Emerg. Med. 2002;9:63-68.ABSTRACT | FULL TEXT

  11. Rapid HeroinDetoxification Under General AnesthesiaLaheij et al.JAMA 2000;283:1143-1143. Neurobiological Adaptations to Psychostimulants and Opiates as a Basis of Treatment DevelopmentSEVARINO et al.Ann. N. Y. Acad. Sci. 2000;909:51-87. RapidOpioidDetoxificationGevirtz et al.JAMA 1998;279:1871-1872.

More Related